Gyre Therapeutics, Inc.
GYRE
$7.14
-$0.51-6.67%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 37.20M | 30.56M | 26.77M | 22.06M | 27.87M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 37.20M | 30.56M | 26.77M | 22.06M | 27.87M |
| Cost of Revenue | 1.74M | 1.63M | 1.15M | 894.00K | 1.18M |
| Gross Profit | 35.45M | 28.94M | 25.62M | 21.16M | 26.70M |
| SG&A Expenses | 30.52M | 19.65M | 20.02M | 15.80M | 22.32M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.08M | 23.64M | 24.60M | 19.79M | 27.21M |
| Operating Income | 120.00K | 6.93M | 2.17M | 2.27M | 663.00K |
| Income Before Tax | -66.00K | 7.63M | 2.24M | 4.64M | 772.00K |
| Income Tax Expenses | 1.30M | 1.69M | 662.00K | 901.00K | 203.00K |
| Earnings from Continuing Operations | -1.37M | 5.94M | 1.58M | 3.73M | 569.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -357.00K | -2.33M | -1.13M | -1.04M | -668.00K |
| Net Income | -1.72M | 3.61M | 442.00K | 2.70M | -99.00K |
| EBIT | 120.00K | 6.93M | 2.17M | 2.27M | 663.00K |
| EBITDA | 815.00K | 7.58M | 2.81M | 2.81M | 1.16M |
| EPS Basic | -0.02 | 0.04 | 0.01 | 0.03 | 0.00 |
| Normalized Basic EPS | -0.01 | 0.03 | 0.00 | 0.02 | 0.00 |
| EPS Diluted | -0.02 | 0.03 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | -0.01 | 0.02 | 0.00 | 0.02 | 0.00 |
| Average Basic Shares Outstanding | 91.16M | 90.85M | 89.12M | 86.42M | 85.95M |
| Average Diluted Shares Outstanding | 91.16M | 103.97M | 102.70M | 101.97M | 85.95M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |